About
Looking for more information?
Contact our responsive and friendly client services team any time.
INVESTOR PRESENTATION - BARD1 LIFE SCIENCES LIMITED
BARD1 LIFE SCIENCES LIMITED
Health Care
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
Read moreMarket Cap
$57.47m
Price at Close
$0.024
4w avg. Volume
2.19m
4w avg. Turnover
$53.53k
Announcements
| announcement | t+2 movement | date |
|---|---|---|
| - | 26 Nov 2020 |
| - | 26 Nov 2020 |
| +4.35% | 25 Nov 2020 |
| +4.35% | 25 Nov 2020 |
| -8.00% | 22 Nov 2020 |
| -4.00% | 30 Oct 2020 |
| -4.00% | 27 Oct 2020 |
| +4.00% | 19 Oct 2020 |
| -3.70% | 22 Sep 2020 |
| 0.00% | 02 Sep 2020 |
Market Data
Current Price
$0.024
52WK HIGH
$0.04
52WK LOW
$0.019
1YR RETURN
-30.30%
1YR RETURN VS. SECTOR
-42.20%
90 DAY RETURN
-20.69%
ASX RANK
1,065
/2,024
SECTOR RANK
9
/14
SHARES OUTSTANDING
2.39b
BARD1 LIFE SCIENCES LIMITED
Health Care
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
Read moreMarket Cap
$57.47m
Price at Close
$0.024
4w avg. Volume
2.19m
4w avg. Turnover
$53.53k
ASX:BD1 is not raising right now
Want to invest?
Contact Us
(03) 9028 2888
clients@freshequities.com
Address
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia